QualityCounts.com
Use this link for 5% off at iHerb.
To address the growing use of ad blockers we now use affiliate links to sites like Amazon.com, streaming services, and others. Affiliate links help sites like QualityCounts.com stay open. Affiliate links cost you nothing but help me support my family. We do not allow paid reviews on this site. As an Amazon Associate I earn from qualifying purchases.  Also, you can donate to ben@qualitycounts.com via Zelle or PayPal.  Click here for the PayPal QR code.
Home | Catalog | Women's short-sleeve t-shirts | Men's long-sleeve t-shirts | Men's short-sleeve t-shirts |
Sweatshirts | Hoodies | Women's long-sleeve t-shirts | Women's classic fit | Men's classic fit

Home iHerb ReliableRx Amazon.com Contact
 Sign-up for newsletter 
 Newsletter Archive
 Newsletter via RSS Feed
 Research on Supplements
 Health Conditions
 Anti-aging Recommendations
 Insulin and Aging
 QualityCounts.com in Time
 Longevity Affiliates:
 Amazon.com
 T-shirts
 

Home > Health Conditions > Diabetes > Invokana (canagliflozin)

Invokana (canagliflozin)

Related Topics:

News & Research:

  • Canagliflozin Reduces Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial - Am J Kidney Dis 2021 May 21 - "acute kidney injury (AKI ... Full recovery of kidney function within 30 days after an AKI event occurred more frequently with canagliflozin versus placebo (53.1% vs 35.4% ... Canagliflozin compared to placebo was associated with a reduced incidence of serious and non-serious kidney-related AEs in patients with T2DM and CKD"
  • FDA Approves Canagliflozin, a First-in-Class Diabetes Drug - Medscape, 3/29/13 - "Canagliflozin is the first in a new class of drug, an oral inhibitor of sodium glucose cotransporter 2 (SGLT2). Inhibition of SGLT2 reduces resorption of glucose in the kidney, resulting in increased urinary glucose excretion, with a consequent lowering of plasma glucose levels as well as weight loss ... But the panel voted 8 to 7 at the same meeting that it had concerns about the cardiovascular safety of canagliflozin, most particularly a possible elevated risk for stroke. In the end, they deemed that current data were insufficient to be certain about this risk and concluded that longer-term follow-up will be required, including completion of the Canagliflozin Cardiovascular Assessment Study (CANVAS)"

Abstracts: